IL139707A0 - Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases - Google Patents

Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Info

Publication number
IL139707A0
IL139707A0 IL13970799A IL13970799A IL139707A0 IL 139707 A0 IL139707 A0 IL 139707A0 IL 13970799 A IL13970799 A IL 13970799A IL 13970799 A IL13970799 A IL 13970799A IL 139707 A0 IL139707 A0 IL 139707A0
Authority
IL
Israel
Prior art keywords
inhibitors
radiation
treatment
growth factor
factor receptor
Prior art date
Application number
IL13970799A
Original Assignee
Imclone Systems Inc
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Uab Research Foundation filed Critical Imclone Systems Inc
Publication of IL139707A0 publication Critical patent/IL139707A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL13970799A 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases IL139707A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8561398P 1998-05-15 1998-05-15
US7961298A 1998-05-15 1998-05-15
US20613898A 1998-12-07 1998-12-07
PCT/US1999/010741 WO1999060023A1 (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
IL139707A0 true IL139707A0 (en) 2002-02-10

Family

ID=27373511

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13970799A IL139707A0 (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Country Status (14)

Country Link
EP (1) EP1080113A4 (en)
JP (1) JP2002515511A (en)
KR (1) KR20010071271A (en)
CN (1) CN1314917A (en)
AU (1) AU4079999A (en)
BR (1) BR9910511A (en)
CA (1) CA2332331A1 (en)
CZ (1) CZ20004224A3 (en)
HK (1) HK1040720A1 (en)
IL (1) IL139707A0 (en)
MX (1) MXPA00011248A (en)
PL (1) PL348634A1 (en)
SK (1) SK17282000A3 (en)
WO (1) WO1999060023A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
EP1206234A4 (en) 1999-06-03 2005-06-01 Jessie L S Au Methods and compositions for modulating cell proliferation and cell death
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
CU22979A1 (en) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF TUMORS OVER-EXPRESSING RECEPTORS WITH KINASE ACTIVITY IN TYPOSINE WASTE
WO2002045653A2 (en) * 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
EP1916001B1 (en) 2002-03-04 2011-05-25 Imclone LLC Human antibodies specific to KDR and uses thereof
KR100968657B1 (en) * 2002-04-02 2010-07-06 네르비아노 메디칼 사이언시스 에스.알.엘. Combined Therapy Against Tumors Comprising Substituted Acryloyl Distamycin Derivatives and Radiotherapy
KR101086533B1 (en) 2002-05-24 2011-11-23 쉐링 코포레이션 Neutralizing human anti-IGFR antibody, a method for producing it and a composition comprising it
JP2007535895A (en) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド Fully human antibody against human insulin-like growth factor-1 receptor
JP2007500248A (en) 2003-06-09 2007-01-11 ワクサル，サムエル Method for inhibiting receptor tyrosine kinase by extracellular antagonist and intracellular antagonist
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
WO2005016967A2 (en) 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies
ATE514783T1 (en) 2003-11-12 2011-07-15 Schering Corp PLASMID SYSTEM FOR EXPRESSING MULTIPLE GENES
PE20050928A1 (en) 2003-11-21 2005-11-08 Schering Corp THERAPEUTIC COMBINATIONS OF ANTI-IGFR1 ANTIBODY
US7598350B2 (en) 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
RU2006146612A (en) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) TREATMENT OF EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR AND CISPLATIN AND INHIBITOR
MX2007006640A (en) 2004-12-03 2007-06-19 Schering Corp Biomarkers for pre-selection of patients for anti-igf1r therapy.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP2100614B8 (en) 2005-06-17 2013-11-20 ImClone LLC Antibody against PDGFR-alpha for use in the treatment of tumours
JP5055284B2 (en) 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Biological markers for predicting anti-cancer responses to insulin-like growth factor-1 receptor kinase inhibitors
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
DK2056874T3 (en) 2006-08-21 2012-10-15 Hoffmann La Roche TUMOR THERAPY WITH ANTI-VEGF ANTIBODY
WO2008100624A2 (en) 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
MX2009010611A (en) * 2007-04-03 2010-03-26 Micromet Ag Cross-species-specific bispecific binders.
US20110243931A1 (en) 2007-09-02 2011-10-06 Thomas Friess Combination therapy with type i and type ii anti-cd20 antibodies
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
AR071891A1 (en) 2008-05-30 2010-07-21 Imclone Llc ANTI-FLT3 HUMAN ANTIBODIES (THIROSINE KINASE 3 RECEPTOR HUMAN FMS TYPE)
UA104868C2 (en) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Method for treating patient having neoplastic tumor according to predicted reaction
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
CN104447995A (en) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
TWI409079B (en) 2009-08-14 2013-09-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with bendamustine
RU2012109451A (en) 2009-08-14 2013-09-27 Роше Гликарт Аг COMBINED THERAPY BASED ON AFUCHOSILY ANTIBODY TO CD20 IN COMBINATION WITH FLUDARABIN AND / OR MITOXANTRON
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
DK2544680T3 (en) 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
CA2795544A1 (en) 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
BR112013014522A2 (en) 2010-12-16 2017-09-26 Roche Glycart Ag afucosylated anti-cd20 antibody and its use, composition and method for treating a cancer patient
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CA2831957A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
EP2817340B1 (en) * 2012-02-23 2020-12-09 Daiichi Sankyo Europe GmbH Her3 inhibitor for modulating radiosensitivity
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2014039855A1 (en) 2012-09-07 2014-03-13 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
AR094403A1 (en) 2013-01-11 2015-07-29 Hoffmann La Roche ANTI-HER3 ANTIBODY COMBINATION THERAPY
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
RU2016141385A (en) 2014-03-24 2018-04-28 Дженентек, Инк. CANCER TREATMENT WITH C-MET ANTAGONISTS AND THEIR CORRELATION WITH HGF EXPRESSION
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN113607945A (en) 2015-07-07 2021-11-05 豪夫迈·罗氏有限公司 Combination therapy of an anti-HER 2 antibody-drug conjugate and a Bcl-2 inhibitor
KR20180100125A (en) 2015-12-03 2018-09-07 아지오스 파마슈티컬스 아이엔씨. MAT2A inhibitor for treating MTAP null cancer
WO2017125429A1 (en) 2016-01-18 2017-07-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
CN110869391A (en) 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 Combination therapy with BET inhibitors, Bcl-2 inhibitors and anti-CD 20 antibodies
EP3658188A1 (en) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
US20200354460A1 (en) * 2017-09-29 2020-11-12 Wuxi Biologics Ireland Limited. Bispecific antibodies against EGFR and PD-1
CN111989092A (en) 2018-04-18 2020-11-24 豪夫迈·罗氏有限公司 Combination therapy of BET inhibitors and proteasome inhibitors
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP0831880A4 (en) * 1995-06-07 2004-12-01 Imclone Systems Inc Antibody and antibody fragments for inhibiting the growth of tumors
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Also Published As

Publication number Publication date
CZ20004224A3 (en) 2002-02-13
BR9910511A (en) 2001-11-20
SK17282000A3 (en) 2002-04-04
HK1040720A1 (en) 2002-06-21
EP1080113A1 (en) 2001-03-07
MXPA00011248A (en) 2004-09-06
CN1314917A (en) 2001-09-26
CA2332331A1 (en) 1999-11-25
JP2002515511A (en) 2002-05-28
KR20010071271A (en) 2001-07-28
WO1999060023A1 (en) 1999-11-25
PL348634A1 (en) 2002-06-03
AU4079999A (en) 1999-12-06
EP1080113A4 (en) 2002-04-17

Similar Documents

Publication Publication Date Title
PL348634A1 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
HUP0201480A3 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
IL134013A (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
EP1073496A4 (en) Improved irradiation catheter and method of use
HUP0203035A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
DE60014581D1 (en) DYNAMIC COOLING OF SKIN TISSUE FOR RADIATION TREATMENT
EP1097165A4 (en) Novel inhibitors of angiogenesis and tumor growth
IL146094A0 (en) Diaminothiazoles and their use for inhibiting protein kinases
AU6528800A (en) Methods and apparatuses for radiation treatment
IL126341A0 (en) Radiation delivery devices and methods of making same
EP1169319A4 (en) Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
AU6887698A (en) Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
HK1043113A1 (en) Telomerase inhibitors and methods of their use
DE60030164D1 (en) 3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVES WITH PROTEIN OF KINASE MODULATING ACTIVITY AND FOR USE IN CANCER THERAPY
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
EP1054979A4 (en) Compositions and methods for sensitizing and inhibiting growth of human tumor cells
GB9811598D0 (en) Diagnosis and treatment of cancer
HK1046915A1 (en) Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase and methods for identification of inhibitors thereof
AU4492000A (en) Determination of pacemaker wenckebach and adjustment of upper rate limit
EP1181374A4 (en) Novel murine and human kinases
EP1161451A4 (en) Human endokine alpha and methods of use
IL153769A0 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
NO20021430L (en) Procedure for Therapeutic Management of Extrauterine Proliferation of Endometrial Tissue, Chronic Pelvic Pain and Ovary Obstruction
AU2002366230A1 (en) Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation